Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Product Surveillance, Postmarketing | 19 | 2021 | 465 | 2.790 |
Why?
|
Adverse Drug Reaction Reporting Systems | 11 | 2018 | 495 | 1.600 |
Why?
|
Computer Communication Networks | 7 | 2020 | 295 | 1.430 |
Why?
|
United States Food and Drug Administration | 16 | 2022 | 1672 | 1.380 |
Why?
|
Comparative Effectiveness Research | 4 | 2019 | 713 | 1.280 |
Why?
|
Electronic Health Records | 18 | 2021 | 4875 | 1.090 |
Why?
|
Databases, Factual | 21 | 2022 | 8075 | 0.870 |
Why?
|
Sentinel Surveillance | 5 | 2018 | 292 | 0.860 |
Why?
|
Fructose | 3 | 2006 | 284 | 0.690 |
Why?
|
Multicenter Studies as Topic | 2 | 2013 | 1727 | 0.600 |
Why?
|
Influenza Vaccines | 3 | 2009 | 780 | 0.580 |
Why?
|
International Classification of Diseases | 2 | 2022 | 924 | 0.520 |
Why?
|
Insurance Claim Review | 5 | 2022 | 746 | 0.490 |
Why?
|
Migraine Disorders | 4 | 2008 | 1713 | 0.450 |
Why?
|
Clinical Laboratory Information Systems | 1 | 2014 | 108 | 0.420 |
Why?
|
Drug Utilization Review | 2 | 2010 | 248 | 0.390 |
Why?
|
Medical Informatics Applications | 1 | 2013 | 180 | 0.380 |
Why?
|
Research Design | 8 | 2019 | 6210 | 0.370 |
Why?
|
Valproic Acid | 1 | 2013 | 443 | 0.350 |
Why?
|
Health Maintenance Organizations | 7 | 2013 | 658 | 0.340 |
Why?
|
Neuroprotective Agents | 2 | 2006 | 957 | 0.340 |
Why?
|
Population Surveillance | 3 | 2009 | 2598 | 0.330 |
Why?
|
Medical Records Systems, Computerized | 3 | 2009 | 1196 | 0.310 |
Why?
|
Health Planning | 2 | 2014 | 232 | 0.310 |
Why?
|
United States | 37 | 2022 | 73150 | 0.300 |
Why?
|
Urticaria | 1 | 2009 | 151 | 0.300 |
Why?
|
Information Systems | 1 | 2010 | 400 | 0.300 |
Why?
|
Data Collection | 4 | 2020 | 3324 | 0.300 |
Why?
|
Data Mining | 1 | 2013 | 560 | 0.300 |
Why?
|
Antifungal Agents | 1 | 2013 | 759 | 0.290 |
Why?
|
Drugs, Generic | 1 | 2013 | 454 | 0.290 |
Why?
|
Health Care Reform | 1 | 2016 | 1262 | 0.280 |
Why?
|
Insurance, Health | 3 | 2021 | 2518 | 0.280 |
Why?
|
Pharmacoepidemiology | 3 | 2016 | 351 | 0.260 |
Why?
|
Models, Econometric | 1 | 2005 | 215 | 0.240 |
Why?
|
Insurance Coverage | 1 | 2016 | 1946 | 0.240 |
Why?
|
Anti-Asthmatic Agents | 2 | 2021 | 577 | 0.230 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1447 | 0.220 |
Why?
|
Pharmaceutical Preparations | 2 | 2022 | 1088 | 0.210 |
Why?
|
Models, Statistical | 5 | 2014 | 5099 | 0.210 |
Why?
|
Anticonvulsants | 1 | 2013 | 1923 | 0.210 |
Why?
|
Health Status Indicators | 1 | 2008 | 971 | 0.200 |
Why?
|
Models, Economic | 1 | 2006 | 718 | 0.200 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3231 | 0.200 |
Why?
|
Software | 4 | 2014 | 4453 | 0.200 |
Why?
|
Health Services Research | 1 | 2009 | 1817 | 0.190 |
Why?
|
Clinical Coding | 2 | 2021 | 186 | 0.190 |
Why?
|
Pilot Projects | 6 | 2021 | 8731 | 0.180 |
Why?
|
Hypoglycemic Agents | 1 | 2013 | 3108 | 0.170 |
Why?
|
Meningococcal Vaccines | 3 | 2012 | 96 | 0.170 |
Why?
|
Humans | 62 | 2022 | 768393 | 0.160 |
Why?
|
Guillain-Barre Syndrome | 2 | 2012 | 127 | 0.160 |
Why?
|
Disease Outbreaks | 1 | 2008 | 1762 | 0.160 |
Why?
|
Arthroplasty, Replacement | 1 | 2022 | 310 | 0.160 |
Why?
|
Biological Products | 3 | 2021 | 934 | 0.160 |
Why?
|
Computer Simulation | 2 | 2014 | 6277 | 0.160 |
Why?
|
Competitive Medical Plans | 2 | 2009 | 26 | 0.160 |
Why?
|
Drug Utilization | 3 | 2021 | 1191 | 0.150 |
Why?
|
Legislation, Drug | 2 | 2004 | 216 | 0.150 |
Why?
|
Drug Approval | 3 | 2011 | 818 | 0.150 |
Why?
|
Time Factors | 11 | 2018 | 40272 | 0.150 |
Why?
|
Algorithms | 7 | 2022 | 14154 | 0.150 |
Why?
|
Internet | 1 | 2010 | 3107 | 0.150 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1890 | 0.150 |
Why?
|
Computer Security | 3 | 2014 | 260 | 0.140 |
Why?
|
Influenza, Human | 1 | 2008 | 1539 | 0.140 |
Why?
|
Technology | 1 | 2019 | 296 | 0.140 |
Why?
|
Lyme Disease | 1 | 2022 | 630 | 0.130 |
Why?
|
Drug Labeling | 1 | 2018 | 250 | 0.120 |
Why?
|
Adrenergic beta-Agonists | 1 | 2016 | 347 | 0.120 |
Why?
|
Quality of Health Care | 1 | 2010 | 4339 | 0.120 |
Why?
|
Osteoarthritis | 1 | 2022 | 1070 | 0.120 |
Why?
|
Risk | 5 | 2014 | 9636 | 0.120 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2019 | 2044 | 0.110 |
Why?
|
Information Storage and Retrieval | 1 | 2019 | 824 | 0.110 |
Why?
|
Orphan Drug Production | 1 | 2014 | 48 | 0.110 |
Why?
|
Medical Records | 1 | 2019 | 1412 | 0.110 |
Why?
|
Public Health Informatics | 1 | 2014 | 109 | 0.110 |
Why?
|
Natural Language Processing | 2 | 2019 | 1202 | 0.110 |
Why?
|
Feasibility Studies | 3 | 2016 | 5313 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 954 | 0.110 |
Why?
|
Antibodies | 1 | 2021 | 2425 | 0.100 |
Why?
|
Adult | 22 | 2022 | 223640 | 0.100 |
Why?
|
Proton Pump Inhibitors | 1 | 2018 | 553 | 0.100 |
Why?
|
Equipment and Supplies | 2 | 2012 | 273 | 0.100 |
Why?
|
Confidentiality | 2 | 2014 | 606 | 0.100 |
Why?
|
Databases as Topic | 1 | 2014 | 475 | 0.100 |
Why?
|
Likelihood Functions | 2 | 2013 | 993 | 0.100 |
Why?
|
Adolescent | 12 | 2021 | 89184 | 0.100 |
Why?
|
Epidemiologic Research Design | 2 | 2014 | 368 | 0.100 |
Why?
|
Biomedical Research | 3 | 2020 | 3464 | 0.100 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2013 | 298 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1813 | 0.090 |
Why?
|
Bupropion | 1 | 2013 | 304 | 0.090 |
Why?
|
Quinoxalines | 1 | 2013 | 297 | 0.090 |
Why?
|
Nicotinic Agonists | 1 | 2013 | 266 | 0.090 |
Why?
|
Benzazepines | 1 | 2013 | 311 | 0.090 |
Why?
|
Middle Aged | 18 | 2021 | 223491 | 0.090 |
Why?
|
Asthma | 2 | 2021 | 6280 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2011 | 509 | 0.090 |
Why?
|
Software Design | 1 | 2010 | 172 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 391 | 0.080 |
Why?
|
Cost-Benefit Analysis | 3 | 2006 | 5538 | 0.080 |
Why?
|
Young Adult | 8 | 2021 | 60049 | 0.080 |
Why?
|
Rare Diseases | 1 | 2014 | 630 | 0.080 |
Why?
|
Vaccines | 2 | 2014 | 842 | 0.080 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 789 | 0.070 |
Why?
|
Benzodiazepines | 2 | 2004 | 1139 | 0.070 |
Why?
|
Observation | 1 | 2009 | 311 | 0.070 |
Why?
|
Drug Prescriptions | 3 | 2013 | 1673 | 0.070 |
Why?
|
Naproxen | 1 | 2007 | 101 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2019 | 2544 | 0.070 |
Why?
|
Bronchodilator Agents | 1 | 2010 | 519 | 0.070 |
Why?
|
Female | 22 | 2021 | 397089 | 0.070 |
Why?
|
Rhabdomyolysis | 1 | 2007 | 152 | 0.070 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2016 | 1189 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2296 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3252 | 0.070 |
Why?
|
Massachusetts | 2 | 2016 | 8902 | 0.070 |
Why?
|
Incidence | 2 | 2022 | 21544 | 0.060 |
Why?
|
Child | 8 | 2020 | 80891 | 0.060 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1261 | 0.060 |
Why?
|
Retrospective Studies | 11 | 2022 | 81801 | 0.060 |
Why?
|
Financing, Government | 1 | 2009 | 473 | 0.060 |
Why?
|
Male | 18 | 2021 | 364902 | 0.060 |
Why?
|
Program Development | 1 | 2012 | 1298 | 0.060 |
Why?
|
Propensity Score | 1 | 2013 | 1962 | 0.060 |
Why?
|
Lactones | 1 | 2007 | 316 | 0.060 |
Why?
|
Prevalence | 2 | 2021 | 15872 | 0.060 |
Why?
|
Economics, Pharmaceutical | 1 | 2005 | 88 | 0.060 |
Why?
|
Sulfones | 1 | 2007 | 448 | 0.060 |
Why?
|
Cerebral Ventricles | 1 | 2007 | 550 | 0.060 |
Why?
|
Computer Systems | 2 | 2018 | 470 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3236 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2877 | 0.060 |
Why?
|
Cerebrospinal Fluid | 1 | 2007 | 545 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2015 | 65379 | 0.060 |
Why?
|
Decision Trees | 1 | 2005 | 509 | 0.050 |
Why?
|
Decision Support Techniques | 2 | 2019 | 2006 | 0.050 |
Why?
|
Hypolipidemic Agents | 1 | 2008 | 609 | 0.050 |
Why?
|
Predictive Value of Tests | 4 | 2015 | 15455 | 0.050 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2008 | 518 | 0.050 |
Why?
|
Cardiovascular Diseases | 3 | 2019 | 15649 | 0.050 |
Why?
|
Aged | 11 | 2021 | 171562 | 0.050 |
Why?
|
Child, Preschool | 3 | 2010 | 42650 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7861 | 0.050 |
Why?
|
Cardiovascular Agents | 1 | 2008 | 849 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 2010 | 1181 | 0.050 |
Why?
|
Cooperative Behavior | 1 | 2008 | 1515 | 0.050 |
Why?
|
Smoking Cessation | 1 | 2013 | 2083 | 0.050 |
Why?
|
Churg-Strauss Syndrome | 1 | 2021 | 75 | 0.050 |
Why?
|
Anti-Anxiety Agents | 1 | 2004 | 405 | 0.050 |
Why?
|
Occupational Health Services | 1 | 2002 | 149 | 0.050 |
Why?
|
Europe | 2 | 2020 | 3439 | 0.050 |
Why?
|
Administration, Inhalation | 2 | 2016 | 1169 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2013 | 2062 | 0.040 |
Why?
|
Medicaid | 2 | 2004 | 2842 | 0.040 |
Why?
|
Logistic Models | 2 | 2013 | 13323 | 0.040 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 969 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2006 | 1735 | 0.040 |
Why?
|
Vaccination | 1 | 2012 | 3431 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2012 | 3579 | 0.040 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 299 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3707 | 0.040 |
Why?
|
Pneumonia | 1 | 2010 | 2163 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2027 | 0.040 |
Why?
|
Cohort Studies | 6 | 2022 | 41795 | 0.040 |
Why?
|
Registries | 1 | 2014 | 8379 | 0.040 |
Why?
|
Sulfonamides | 1 | 2007 | 1980 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 1995 | 5512 | 0.040 |
Why?
|
Infant | 2 | 2010 | 36510 | 0.040 |
Why?
|
Consumer Product Safety | 1 | 2018 | 122 | 0.040 |
Why?
|
Pyrazoles | 1 | 2007 | 2021 | 0.040 |
Why?
|
Program Evaluation | 3 | 2018 | 2505 | 0.030 |
Why?
|
Pregnant Women | 1 | 2021 | 577 | 0.030 |
Why?
|
Pyridines | 1 | 2007 | 2889 | 0.030 |
Why?
|
Quality of Life | 2 | 2008 | 13503 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 12241 | 0.030 |
Why?
|
Investigational New Drug Application | 1 | 1995 | 5 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3486 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 2007 | 2913 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2019 | 794 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 3243 | 0.030 |
Why?
|
Health Education | 1 | 2002 | 1057 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 810 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3743 | 0.030 |
Why?
|
Decision Making | 1 | 2008 | 3953 | 0.030 |
Why?
|
Depressive Disorder | 1 | 2007 | 3736 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2007 | 3411 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2139 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2007 | 4076 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2016 | 6318 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2007 | 2972 | 0.030 |
Why?
|
New Jersey | 2 | 2004 | 296 | 0.030 |
Why?
|
Drug Evaluation | 1 | 1995 | 642 | 0.030 |
Why?
|
Risk Assessment | 2 | 2013 | 24318 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2004 | 1664 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2013 | 7955 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2018 | 417 | 0.030 |
Why?
|
Drugs, Investigational | 1 | 1995 | 213 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2276 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 1995 | 13697 | 0.030 |
Why?
|
Drug Therapy | 1 | 1995 | 504 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2021 | 3731 | 0.020 |
Why?
|
Prospective Studies | 3 | 2013 | 54920 | 0.020 |
Why?
|
Privacy | 1 | 2014 | 233 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2019 | 21162 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2011 | 162 | 0.020 |
Why?
|
New York | 2 | 2004 | 884 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2931 | 0.020 |
Why?
|
Japan | 1 | 1995 | 1418 | 0.020 |
Why?
|
Sample Size | 1 | 2014 | 848 | 0.020 |
Why?
|
Vaccines, Conjugate | 1 | 2012 | 334 | 0.020 |
Why?
|
Health Promotion | 1 | 2002 | 2209 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4859 | 0.020 |
Why?
|
Case-Control Studies | 4 | 2010 | 22296 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2021 | 4357 | 0.020 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2014 | 407 | 0.020 |
Why?
|
Albuterol | 1 | 2010 | 211 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2698 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3064 | 0.020 |
Why?
|
Androstadienes | 1 | 2010 | 348 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2005 | 10377 | 0.020 |
Why?
|
Osteoporosis | 1 | 2018 | 1606 | 0.020 |
Why?
|
Pregnancy | 3 | 2021 | 30200 | 0.020 |
Why?
|
Teratogens | 1 | 2008 | 117 | 0.020 |
Why?
|
Tobacco Use Disorder | 1 | 2013 | 708 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2002 | 4047 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2004 | 4429 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2007 | 286 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2012 | 1337 | 0.020 |
Why?
|
History, 20th Century | 1 | 1995 | 2771 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2007 | 11516 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2008 | 26375 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3836 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3543 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14737 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10776 | 0.020 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 429 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2011 | 1397 | 0.020 |
Why?
|
Documentation | 1 | 2011 | 917 | 0.020 |
Why?
|
Bone Density | 1 | 2018 | 3559 | 0.010 |
Why?
|
Risk Factors | 4 | 2018 | 74962 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5375 | 0.010 |
Why?
|
Mental Disorders | 1 | 2004 | 6876 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 1517 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8753 | 0.010 |
Why?
|
Brain | 1 | 2007 | 27454 | 0.010 |
Why?
|
Prenatal Diagnosis | 1 | 2007 | 1274 | 0.010 |
Why?
|
Outpatients | 1 | 2008 | 1604 | 0.010 |
Why?
|
Prenatal Care | 1 | 2007 | 1159 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 36849 | 0.010 |
Why?
|
Odds Ratio | 1 | 2010 | 9682 | 0.010 |
Why?
|
Self Efficacy | 1 | 2002 | 643 | 0.010 |
Why?
|
Awareness | 1 | 2002 | 653 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39407 | 0.010 |
Why?
|
American Heart Association | 1 | 2002 | 1051 | 0.010 |
Why?
|
Probability | 1 | 2002 | 2482 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3438 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4941 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2019 | 59686 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 14784 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2004 | 2240 | 0.010 |
Why?
|
Age Factors | 1 | 2010 | 18471 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 15939 | 0.010 |
Why?
|
Health Behavior | 1 | 2002 | 2647 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20224 | 0.000 |
Why?
|
Infant, Newborn | 1 | 2007 | 26411 | 0.000 |
Why?
|